Search results
Results from the WOW.Com Content Network
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. [30] [28] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. [31]
In addition to chemotherapy added to radiation, chemotherapy to treat recurrent cervical cancer and the development of bevacizumab, Monk is also a world leader in advancing immune therapy in cervical cancer. He is the steering committee chair and co-first author for EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9. [14]
Genentech's Medicine Avastin Plus Chemotherapy Improved Survival in Women with Advanced Cervical Cancer, Compared to Chemotherapy Alone -- First Phase III Study of Avastin in This Difficult-to ...
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
Results from a phase 3 clinical trial show promise for a new standard of care for treating people with advanced cervical cancer. The new treatment includes a combination of induction chemotherapy ...
gastric cancer or gastroesophageal junction adenocarcinoma ... Bevacizumab [14] Avastin: mab: humanized: ... relapsed or refractory cervical cancer [120] [121]
After years of decline, cervical cancer rates are rising in some demographics in the United States — primarily low-income women and those in their 30s and 40s. If the disease spreads in the body ...
Cervical cancer is the 12th-most common cancer in women in the UK (around 3,100 women were diagnosed with the disease in 2011), and accounts for 1% of cancer deaths (around 920 died in 2012). [148] With a 42% reduction from 1988 to 1997, the NHS-implemented screening programme has been highly successful, screening the highest-risk age group (25 ...